Johnson & Johnson

NYSE:JNJ   3:59:57 PM EDT
-3.20 (-1.94%)
4:46:44 PM EDT: $162.38 +0.47 (+0.29%)
Other Pre-Announcement

Aspen Pharmacare FY HEPS From Total Ops 1 461,2 Cents

Published: 08/31/2022 11:26 GMT
Johnson & Johnson (JNJ) - Jse: Apn - Reviewed Provisional Group Financial Results for the Year Ended 30 June 2022 and Dividend Declaration.
Aspen Pharmacare - FY Headline Earnings per Share From Total Operations Increased by 31% (+31% in Cer) to 1 461,2 Cents.
Aspen Pharmacare - FY Dividend Declared to Shareholders Increased by 24% to 326 Cents per Ordinary Share.
Aspen Pharmacare -fy Revenue From Continuing Operations Increased by 2% (+5% in Constant Exchange Rate ("cer")) to R38,6 Billion.
Aspen Pharmacare - Sees Organic Cer Revenue Growth of Between 3% and 7%, (excluding Potential Aspenovax Orders), in the Year Ahead.
Aspen Pharmacare - Declining Demand From Johnson & Johnson Will Have Unfavourable Impact on Manufacturing Performance in 2023 FY.
Aspen Pharmacare - Sales Will Be Heavily Weighted Towards Second Half of Year.
Aspen Pharmacare - Operating Expenses Expected to Continue Tracking Below Percentage Growth in Revenue in Year Ahead.